Point72 Middle East FZE’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Point72 Middle East FZE’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-6,543	Closed	-$34.2K	–	1425
2023 Q4	$34.2K	Buy	6,543 +1,569	+32%	+$15.5K	﹤0.01%	1321
2023 Q3	$78.4K	Buy	+4,974	New	+$89.4K	﹤0.01%	1185
2023 Q2	–	Sell	-863	Closed	-$24.5K	–	2150
2023 Q1	$24.5K	Sell	863 -946	-52%	-$28.1K	﹤0.01%	1392
2022 Q4	$52.9K	Buy	+1,809	New	+$57.5K	﹤0.01%	1440

Other funds holding EGRX

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.82% 1-Year Est. Return

Point72 Middle East FZE's EGRX Position: Q1 2024 in Review

Point72 Middle East FZE sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2024, closing a stake of 6,543 shares — an estimated $34.2K sold.

Point72 Middle East FZE first reported a position in EGRX in Q4 2022 and held it in 4 quarters. The position peaked at $78.4K in Q3 2023. 91 funds tracked by Wall St. Rank hold EGRX as of Q1 2024.

Point72 Middle East FZE reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2024 after selling out during the quarter.
Point72 Middle East FZE sold 6,543 Eagle Pharmaceuticals, Inc. shares in Q1 2024, an estimated $34.2K.
Point72 Middle East FZE first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2022 and held it in 4 quarters.
Point72 Middle East FZE's Eagle Pharmaceuticals, Inc. position peaked at $78.4K in Q3 2023.
91 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2024.

Based on Point72 Middle East FZE's 13F filing for Q1 2024.